vfend 200 mg mobic

Refer to the patient leaflet for more detailed instructions for use.EU/1/02/212/001 VFEND 50 mg Film-coated tablets; Pack size 2 tablets; BlisterEU/1/02/212/002 VFEND 50 mg Film-coated tablets; Pack size 10 tablets; BlisterEU/1/02/212/003 VFEND 50 mg Film-coated tablets; Pack size 14 tablets; BlisterEU/1/02/212/004 VFEND 50 mg Film-coated tablets; Pack size 20 tablets; BlisterEU/1/02/212/005 VFEND 50 mg Film-coated tablets; Pack size 28 tablets; BlisterEU/1/02/212/006 VFEND 50 mg Film-coated tablets; Pack size 30 tablets; BlisterEU/1/02/212/007 VFEND 50 mg Film-coated tablets; Pack size 50 tablets; BlisterEU/1/02/212/008 VFEND 50 mg Film-coated tablets; Pack size 56 tablets; BlisterEU/1/02/212/009 VFEND 50 mg Film-coated tablets; Pack size 100 tablets; BlisterEU/1/02/212/010 VFEND 50 mg Film-coated tablets; Pack size 2 tablets; BottleEU/1/02/212/011 VFEND 50 mg Film-coated tablets; Pack size 30 tablets; BottleEU/1/02/212/012 VFEND 50 mg Film-coated tablets; Pack size 100 tablets; BottleEU/1/02/212/013 VFEND 200 mg Film-coated tablets; Pack size 2 tablets; BlisterEU/1/02/212/014 VFEND 200 mg Film-coated tablets; Pack size 10 tablets; Blister EU/1/02/212/015 VFEND 200 mg Film-coated tablets; Pack size 14 tablets; BlisterEU/1/02/212/016 VFEND 200 mg Film-coated tablets; Pack size 20 tablets; BlisterEU/1/02/212/017 VFEND 200 mg Film-coated tablets; Pack size 28 tablets; BlisterEU/1/02/212/018 VFEND 200 mg Film-coated tablets; Pack size 30 tablets; BlisterEU/1/02/212/019 VFEND 200 mg Film-coated tablets; Pack size 50 tablets; BlisterEU/1/02/212/020 VFEND 200 mg Film-coated tablets; Pack size 56 tablets; BlisterEU/1/02/212/021 VFEND 200 mg Film-coated tablets; Pack size 100 tablets; BlisterEU/1/02/212/022 VFEND 200 mg Film-coated tablets; Pack size 2 tablets; BottleEU/1/02/212/023 VFEND 200 mg Film-coated tablets; Pack size 30 tablets; BottleEU/1/02/212/024 VFEND 200 mg Film-coated tablets; Pack size 100 tablets; BottleEU/1/02/212/025 VFEND 200 mg Powder for solution for infusion; VialEU/1/02/212/026 VFEND 40 mg/ml Powder for oral suspension; BottleEU/1/02/212/027 VFEND 200 mg Powder and Solvent for solution for infusion; Vial, BagEU/I/02/212/028 VFEND 50 mg Film-coated tablets; Pack size 2 tablets; Blister (PVDC)EU/I/02/212/029 VFEND 50 mg Film-coated tablets; Pack size 10 tablets; Blister (PVDC)EU/I/02/212/030 VFEND 50 mg Film-coated tablets; Pack size 14 tablets; Blister (PVDC)EU/I/02/212/031 VFEND 50 mg Film-coated tablets; Pack size 20 tablets; Blister (PVDC)EU/I/02/212/032 VFEND 50 mg Film-coated tablets; Pack size 28 tablets; Blister (PVDC)EU/I/02/212/033 VFEND 50 mg Film-coated tablets; Pack size 30 tablets; Blister (PVDC)EU/I/02/212/034 VFEND 50 mg Film-coated tablets; Pack size 50 tablets; Blister (PVDC)EU/I/02/212/035 VFEND 50 mg Film-coated tablets; Pack size 56 tablets; Blister (PVDC)EU/I/02/212/036 VFEND 50 mg Film-coated tablets; Pack size 100 tablets; Blister (PVDC)EU/I/02/212/037 VFEND 200 mg Film-coated tablets; Pack size 2 tablets; Blister (PVDC)EU/I/02/212/038 VFEND 200 mg Film-coated tablets; Pack size 10 tablets; Blister (PVDC)EU/I/02/212/039 VFEND 200 mg Film-coated tablets; Pack size 14 tablets; Blister (PVDC)EU/I/02/212/040 VFEND 200 mg Film-coated tablets; Pack size 20 tablets; Blister (PVDC)EU/I/02/212/041 VFEND 200 mg Film-coated tablets; Pack size 28 tablets; Blister (PVDC)EU/I/02/212/042 VFEND 200 mg Film-coated tablets; Pack size 30 tablets; Blister (PVDC)EU/I/02/212/043 VFEND 200 mg Film-coated tablets; Pack size 50 tablets; Blister (PVDC)EU/I/02/212/044 VFEND 200 mg Film-coated tablets; Pack size 56 tablets; Blister (PVDC)EU/I/02/212/045 VFEND 200 mg Film-coated tablets; Pack size 100 tablets; Blister (PVDC)Detailed information on this medicinal product is available on the website of the European Medicines Agency.

Voriconazole should be administered with caution to patients with potentially proarrhythmic conditions, such as: Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.Coadministration with CYP3A4 substrates, terfenadine, astemizole, cisapride, pimozide or quinidine since increased plasma concentrations of these medicinal products can lead to QTc prolongation and rare occurrences of torsades de pointes (see section 4.5).Coadministration with rifampicin, carbamazepine and phenobarbital since these medicinal products are likely to decrease plasma voriconazole concentrations significantly (see section 4.5).Coadministration of standard doses of voriconazole with efavirenz doses of 400 mg once daily or higher is contraindicated, because efavirenz significantly decreases plasma voriconazole concentrations in healthy subjects at these doses. There have been rare cases of torsades de pointes in patients taking voriconazole who had risk factors, such as history of cardiotoxic chemotherapy, cardiomyopathy, hypokalaemia and concomitant medicinal products that may have been contributory. • This medicinal product is for single use only and any unused solution should be discarded.